Home » What do non-eosinophilic asthma and airway remodelling tell us about persistent asthma?

TITLE

What do non-eosinophilic asthma and airway remodelling tell us about persistent asthma?

AUTHOR(S)

Gibson, Peter G.

PUB. DATE

December 2007

SOURCE

Thorax;Dec2007, Vol. 62 Issue 12, p1034

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

The author reflects on the study that directs drug discovery programmes and effective treatment for most steps in the eosinophilic asthma pathway in Great Britain. It stated that the list includes interventions that act at discrete levels such as allergen avoidance, allergen immunotherapy, and anti-immunoglobulin E antibodies. It concludes that the persistence of asthma teaches that there is much more to learn about the pathogenesis and treatment of the said condition.

ACCESSION #

27885445

Related Articles

Discusses the pharmacology, efficacy, dosage, adverse effects and economics of omalizumab, a recombinant humanized anti-IgE antibody for allergic asthma. Inhibition of the immune system's response to allergens; Exhibition of a similar pharmacokinetic profile in adults, adolescents and children;...

As clinical experience with omalizumab increases, questions arise from clinicians that are not answered in the product insert or clinical reports. How does this drug really work? There surely must be more than the simple reduction of free IgE which, in and of itself, causes no disease. Can...

Despite both efficacy and immunotolerogenic effects, many clinicians still are reluctant to use allergen-specific immunotherapy (SIT) because of the potential for acute allergic reactions. The anti-immunoglobulin E monoclonal antibody, omalizumab, is approved by the U.S. Food and Drug...

The treatment of asthma and allergic rhinitis using unique, humanized anti-IgE monoclonal antibodies with very particular binding specificities is now supported by the results of multiple phase II and III human clinical studies. The therapeutic efficacy of this approach is attributable to...

Despite the advanced and increasing understanding of the pathophysiology of asthma and other allergic diseases, current treatment remains unspecific and targets late events within the allergic cascade. Therefore, a novel and promising approach to treat allergic asthma is antagonizing IgE by...

Presents an abstract of the study 'Treatment of Childhood Asthma With Anti-immunoglobulin E Antibody (Omalizumab),' by H. Milgrom, W. Berger, A. Nayak, et al., published in the August 2001 issue of the 'Pediatrics' journal. Comment on the study.

The article focuses on the process of drug discovery and development. It provides a timeline of the phases of drug development and discovery including prediscovery, preclinical that takes three to six years, and investigational new drugs that takes six to seven years. It also presents a table...

Immunoglobulin E (IgE) plays a central role in the development of allergic diseases. In sensitized individuals, IgE antibodies bind to receptors on mast cell and basophil surfaces, releasing preformed and newly generated mediators that initiate an immunologic cascade and inflammatory symptoms....

The development of anti-immunoglobulin E (IgE) antibodies for prophylactic and therapeutic applications in allergic diseases has taken nearly 20 years. Limited usage has been approved for allergic asthma. The usage in other allergic indications is in active development and may take an additional...